Trump administration weighs Marshall for FDA as Overton wobbles
The Kansas Republican senator, who just lost his reelection bid, is seen as a stronger potential nominee.
Republicans are considering Sen. Roger Marshall as a potential nominee to lead the Food and Drug Administration (FDA), according to sources familiar with the matter. The Kansas Republican, who recently lost his reelection bid, is seen as a more promising candidate than Heidi Overton, who is facing opposition from anti-abortion activists and moderate Republicans.
Republicans have only a month and a half left in their majority to confirm President Donald Trump's nominees, and if Overton's nomination fails or is pulled, Marshall could step in. Marshall, who previously served in the House, currently serves on the Senate health committee. The Senate health committee is set to vote on Overton's nomination on Wednesday, but as of now, it's unclear if the White House will move on an alternative nominee.
No final decision has been made regarding Overton's nomination, but there's an understanding in the Senate that her chances of confirmation are slim. The FDA has been operating under acting leadership since Marty Makary was removed in May due to disagreements over the authorization of flavored vapes and pressure from anti-abortion Republicans pushing for restrictions on abortion pill mifepristone.
Kyle Diamantas, a former agency official, is currently serving as the acting FDA commissioner but is reportedly looking to leave the position regardless of the outcome with Overton's nomination.
Written by urgent.news from Semafor's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.